Aiforia Technologies Plc – Managers’ Transactions – Thomas Rosqvist

Aiforia Technologies Plc, MANAGERS’ TRANSACTIONS, December 29, 2025 2:00 p.m. EET

Aiforia Technologies Plc has received a notification from Thomas Rosqvist, Aiforia Technologies Plc's Chief Technology Officer and a member of management team, of a transaction made with Aiforia Technologies Plc’s financial instrument, according to the Article 19 of EU Market Abuse Regulation.

Detailed information about the transaction is given here under.

Aiforia Technologies Plc - Managers' transactions - Rosqvist

____________________________________________

Person subject to the notification requirement
Name: Rosqvist, Thomas
Position: Other senior manager
Issuer: Aiforia Technologies Plc
LEI: 743700TJRVBX7420Y723

Notification type: INITIAL NOTIFICATION
Reference number: 135626/5/6

____________________________________________

Transaction date: 2025-12-29
Venue not applicable
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
Instrument name: Aiforia Technologies 2025D
Nature of the transaction: ACCEPTANCE OF A STOCK OPTION
(X) Linked to stock option programme

Transaction details
(1): Volume: 50,000 Unit price: 0.00 EUR

Aggregated transactions
(1): Volume: 50,000 Volume weighted average price: 0.00 EUR

Further inquiries
Veli-Matti Parkkonen, CFO, Aiforia Technologies Plc
tel. +358 405 009 878
https://investors.aiforia.com/

Certified Adviser 
UB Corporate Finance Ltd
ubcf@unitedbankers.fi

About Aiforia 

Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions deployed, Aiforia is making a significant impact on pathology and healthcare. In Europe, Aiforia is the leading provider of CE-IVD marked AI-powered solutions for digital pathology.

Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France, and maintains a network of local representatives across Europe and North America. Aiforia’s diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient. 

Find out more at www.aiforia.com